EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stratified and Quantified Score Construction of Low‐Grade Glioma Samples Based on TP53 Signaling Pathway

Xinlong Ma iD, Kun Tian, Yongzhang Li, Lipeng Qin iD, Xin Guo iD

BioMed Research International · 2026-01 · 2026 (1)

DOI: 10.1155/bmri/2147185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Research International, online erschienen am 31.03.2026. Verfasst von Xinlong Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Yuquan Hospital, Tsinghua University, Beijing, China, tsinghua.edu.cn. Hauptthemen laut MEDLINE: Glioma, Tumor Suppressor Protein p53, Signal Transduction, Brain Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei Yanzhao Golden Platform Talent Gathering Plan Backbone Talent Project, Natural Science Foundation of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study is aimed at distinguishing the phenotypes of low‐grade gliomas based on the P53 signaling pathway gene set, revealing the transcriptomic changes in different phenotypes, screening phenotype‐related feature genes, constructing a TP53 score, quantitatively describing TP53‐related phenotypes, and predicting the response of glioma patients to chemotherapy.

Methods

We obtained transcriptomic sequencing data of low‐grade glioma samples from the Cancer Genome Atlas (TCGA) database. Based on the expression levels of genes related to prognosis in the P53 signaling pathway, we performed consensus clustering on glioma samples to describe sample heterogeneity. Through differentially expressed genes (DEGs), we showed the transcriptomic changes between different TP53 phenotypes. We used univariate COX analysis to remove redundant information and retain prognostic factors. We used principal component analysis to retain the first principal component of the prognostic factors as the TP53 score. We elucidated the correlation between the TP53 score and mRNAsi, immune cell subtypes, and EMT markers.

Results

We obtained the TP53 genes and screened 14 prognostic risk factors through univariate COX analysis. Based on prognostic risk factors, we classified glioma samples into TP53 clusters using consensus clustering, describing sample heterogeneity. The prognosis and immune cell microenvironment characteristics differed between TP53 clusters. Among the DEGs between TP53 clusters, we screened 38 as prognostic factors. We used the first principal component of these 38 genes as the TP53 score. The TP53 score was positively correlated with immune cell subtypes and EMT markers and negatively correlated with mRNAsi. High TP53 glioma samples were more sensitive to vorinostat, elesclomol, gefitinib, AICAR, axitinib, and bosutinib.

Conclusion

The TP53 score based on the P53 signaling pathway can describe the heterogeneity of glioma samples and distinguish different immune microenvironment characteristics and prognostic features. A high TP53 score indicates more active epithelial–mesenchymal transition and lower tumor stemness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaTumor Suppressor Protein p53Signal TransductionBrain NeoplasmsHumansGene Expression Regulation, NeoplasticPrognosisGene Expression ProfilingNeoplasm GradingTranscriptomeBiomarkers, TumorFemale

Stichwörter der Autor:innen

TP53chemotherapyheterogeneitylow-grade glioma

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurosurgery, Yuquan Hospital, Tsinghua University, Beijing, China, tsinghua.edu.cn.
  • Department of Breast Surgery, Beijing Haidian Maternal and Child Health Hospital, Beijing, China.
  • Research Center, Hebei Province Hospital of Chinese Medicine, Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Shijiazhuang, Hebei, China, hbtcm.edu.cn.
  • Hebei Key Laboratory of Turbidity Toxin Syndrome, Shijiazhuang, Hebei, China.
  • Department of Neurosurgery, Hebei Province Hospital of Chinese Medicine, Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Shijiazhuang, Hebei, China, hbtcm.edu.cn.
  • Department of Pathology and Laboratory Medicine, Department of Pathology, Kanazawa Medical University, Uchinada, Ishikawa, Japan, kanazawa-med.ac.jp.

ORCID-Profile: Xinlong Ma, Lipeng Qin, Xin Guo

Förderung

  • Hebei Yanzhao Golden Platform Talent Gathering Plan Backbone Talent Project
  • Natural Science Foundation of Hebei Province

Zitieren

APA

Ma, X., Tian, K., Li, Y., Qin, L., & Guo, X. (2026). Stratified and Quantified Score Construction of Low‐Grade Glioma Samples Based on TP53 Signaling Pathway. BioMed Research International, 2026(1). https://doi.org/10.1155/bmri/2147185

Vancouver

Ma X, Tian K, Li Y, Qin L, Guo X. Stratified and Quantified Score Construction of Low‐Grade Glioma Samples Based on TP53 Signaling Pathway. BioMed Research International. 2026;2026(1). doi:10.1155/bmri/2147185

BibTeX
@article{Ma2026,
  author = {Ma, Xinlong and Tian, Kun and Li, Yongzhang and Qin, Lipeng and Guo, Xin},
  title = {Stratified and Quantified Score Construction of Low‐Grade Glioma Samples Based on TP53 Signaling Pathway},
  journal = {BioMed Research International},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/bmri/2147185}
}
Kostenlos starten →